LTRN

Lantern Pharma Inc. (LTRN) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Lantern Pharma Inc. is an artificial intelligence (A.I.) focused biopharmaceutical company developing cancer therapies. The company utilizes its proprietary RADR® platform to identify drug candidates and patient populations. Its portfolio includes three clinical-stage oncology candidates (LP-300, LP-184, LP-284) and an Antibody Drug Conjugate (ADC) program. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Reduction: The net loss for the six months ended June 30, 2025, decreased by approximately $1.53 million (15%) compared to the same period in 2024, driven primarily by lower R&D expenses.
• R&D Expense Decline: R&D expenses decreased by approximately $1.81 million (22%) year-over-year for the six-month period. This was primarily due to a $1.79 million decrease in research study costs, partially offset by increased licensing expenses.
• Liquidity Position: Total cash, cash equivalents, and marketable securities decreased significantly from approximately $29.5 million at June 30, 2024, to $15.9 million at June 30, 2025. This reduction reflects net cash used in operating activities of $8.31 million, partially offset by net cash provided by investing activities of $6.83 million (due to net redemptions of marketable securities).
• Interest Income: Interest income decreased by approximately $125,000 year-over-year for the six-month period, reflecting lower yields or balances on invested cash.

Outlook, Risks, and Management Commentary

• Going Concern: The company has incurred significant losses and expects to continue doing so. Management states that existing cash and marketable securities are sufficient to fund operations at least into June 2026. However, substantial additional funding will be required in the near future, raising substantial doubt about the company's ability to continue as a going concern without raising capital.
• Capital Raising: In July 2025, the company entered into an "at-the-market" (ATM) Sales Agreement to sell up to $15.53 million of common stock. As of August 12, 2025, approximately $80,000 had been raised under this agreement.
• Clinical Progress:
  • LP-300: Advancing in the Phase 2 Harmonic™ trial for never-smokers with advanced non-small cell lung cancer (NSCLC). The company transitioned CRO services from Fortrea Inc. to other providers in July 2025.
  • LP-184 (STAR-001): Advancing in a Phase 1 trial for solid tumors and CNS cancers (via subsidiary Starlight Therapeutics).
  • LP-284: Advancing in a Phase 1 trial for hematological cancers.
  • ADC Program: Preclinical optimization continues, leveraging the RADR® platform.
• Risks: Key risks include the inability to secure sufficient funding, failure of clinical trials, regulatory hurdles, and reliance on third-party manufacturers. The company also notes potential impacts from U.S. trade policies and tariffs on foreign service providers.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the "June 2026" liquidity projection given the high burn rate and potential for clinical trial cost overruns.
• ATM Utilization: Monitor the pace of share sales under the new ATM agreement and the resulting dilution to existing shareholders.
• CRO Transition: Assess the impact of the CRO transition for the LP-300 Phase 2 trial on timelines and costs.
• Investment Portfolio: Review the composition of marketable securities ($9.8M) and the impact of unrealized losses/gains on the balance sheet.
• Stock-Based Compensation: Note that stock-based compensation totaled $308,376 for the six months ended June 30, 2025, representing a non-cash expense that reduces net loss but impacts equity.